Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Age \> 65 * Comorbidities score, PS and frailty score according to table 1 * No dementia, faecal or urinary incontinence, repeated falls * ADL = 0, IADL = 0-1 * Life expectancy at least 12 weeks * Creatinin clearance \> = 30 ml/mn (according to Cockcrofts-Gault formula) * Competency to give written informed consent * Haematological functions as follows : neutrophiles count \> 1.5 x 109/l and platelets \> 100 x 109/l hemoglobin \> 9,5 g/dl - Hepatic function as follows : Bilirubin \< 1,25 LNS ASAT / ALAT \<5 x NAlcPh \<5 x N * PS \< 3 * cerebral metastasis eligible if asymptomatic * Histologically or cytologically confirmed NSCLC * Stage IV/IIIB4 (T4 with pleural effusion) * No prior chemotherapy * relapses of previous NSCLC treated by surgery or radiotherapy are eligible, if the target is measurable out of initial radiotherapy field and if cytological or histological proof * At least one measurable target lesion by RECIST guidelines Exclusion Criteria: * symptomatic cerebral metastasis * Any severe comorbidity calculated by Charlson score according to table 1 * ADL \> 0 and IADL \> 1- performance status \>2 (ECOG) * peripheral neuropathy grade 2 or more * dementia, repeated falls, urinary or faecal incontinence * contra-indication to corticosteroids * contra indication to a product of this study * unwilling or unable to comply with study requirements, for personal, family, sociologic, geographic or any other reason * inability of the subject to give written informed consent * lack of liberty following legal or administrative decision * hypersensitivity to polysorbate * hypersensitivity to erlotinib or any excipients of this product * unusual hereditary disorders, as galactosemia, deficit in lactase and syndrome of malabsorption in glucose or galactose * participation in concomitant clinical trial * bronchioloalveolar or neuroendocrine or composite carcinoma * superior vena cava syndrome